Document Detail

In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy.
MedLine Citation:
PMID:  8305539     Owner:  NLM     Status:  MEDLINE    
Treatment of cancer patients with interleukin-2 has resulted in clinical regression of metastatic disease. The ability to predict which patients will respond to therapy could result in more efficacious and possibly less toxic treatments. Hence, attempts have been made to correlate patient parameters or in vitro characteristics with clinical response to immunotherapy. Some patient factors have been identified as prognostically favorable. However, parameters modulated by interleukin-2 have not been predictive of clinical outcome. Exciting new evidence does exist regarding in vitro characteristics of tumor-infiltrating lymphocytes. Measurement of the cytolytic ability of melanoma tumor-infiltrating lymphocytes may enhance our understanding of the immune-mediated antitumor response and lead to a new generation of selective immunotherapies.
D J Schwartzentruber
Related Documents :
25175849 - The effect of rubber dam usage on the survival rate of teeth receiving initial root can...
11579119 - Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-gd3 mo...
9591809 - An estimate of the annual direct cost of treating cutaneous melanoma.
12845209 - Mucosal metastases in malignant melanoma.
15073859 - A phase ii trial of vinorelbine tartrate in patients with disseminated malignant melano...
12883369 - Malignant melanoma in south africans of mixed ancestry: a retrospective analysis.
2984209 - Adjuvant chemotherapy for malignant fibrous histiocytoma in the femur and tibia.
21650569 - Resurrecting brownfields.
18521429 - Adjuvant radiation therapy of retroperitoneal sarcoma: the role of intraoperative radio...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in oncology     Volume:  5     ISSN:  1040-8746     ISO Abbreviation:  Curr Opin Oncol     Publication Date:  1993 Nov 
Date Detail:
Created Date:  1994-03-16     Completed Date:  1994-03-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9007265     Medline TA:  Curr Opin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1055-8     Citation Subset:  IM    
National Cancer Institute, Bethesda, Maryland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carcinoma, Renal Cell / therapy*
Clinical Trials as Topic
Interleukin-2 / therapeutic use*
Kidney Neoplasms / therapy*
Melanoma / therapy*
Predictive Value of Tests
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular therapy.
Next Document:  Retinoids.